Insmed
$108.59Change from previous close: −4.86%Absolute change: −$5.55
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $23.71B
- Enterprise value
- $23.29B
- Forward P/E
- 140.2
- PEG
- 1.09
- Price/book
- 31.3
- Price/sales
- 20.8
- EV/EBITDA
- -29.3
- EV/revenue
- 20.5
Profitability and growth
- Gross margin
- 83.5%
- Operating margin
- -23.8%
- Net margin
- -76.9%
- ROE
- -87.2%
- ROA
- -22.2%
- Revenue growth (year over year)
- 296.1%
Financial health
- Total cash
- $1.16B
- Total debt
- $739.72M
- Debt/equity
- 0.98
- Current ratio
- 3.72
- Quick ratio
- 3.14
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $197.74
- Median price target
- $195.00
- High price target
- $243.00
- Low price target
- $169.00
- Analysts with a price target
- 23
- Consensus
- Strong buy
- Forward EPS
- $0.77
- EPS estimate, current year
- -$1.54
Shares and trading
- Beta
- 0.82
- Average volume
- 2.45M
- Shares outstanding
- 218.38M
- Float
- 216.93M
- Institutional ownership
- 105.0%
- Insider ownership
- 0.5%
- Short interest (% of float)
- 5.6%
- Short ratio (days)
- 5.74